BRCA1 and breast cancer: In a Dutch study, the impact of incorporating the PRS into risk calculations for 1331 non-BRCA1/2 carriers was investigated regarding screening procedures aligned with Dutch IKNL [56], UK NICE [57], and US NCCN [58] BC screening guidelines.